Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06065540 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,734
- Enrollment target
- 20
- Study locations
NCT06065540: Completed Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S.
NCT06065540 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by Novo Nordisk A/S. The registered enrollment target is 2,734 participants, roughly in line with the 2,939-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target. The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06065540, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,734 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
Primary Outcome
Measured in percentage-points.
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Cagrilintide
- DRUG Placebo cagrilintide
- DRUG Placebo semaglutide
Study Locations (20)
California
- Velocity Clinical Res-Banning - Banning
- Velocity Clin Res-Chula Vista - Chula Vista
- John Muir Physicians Network - Concord
- Headlands Research California, LLC - Escondido
- Velocity Clin Res Gardena - Gardena
- Velocity Clin Res San Diego - La Mesa
- Loma Linda Univ Hlth Cr Endo - Loma Linda
- Facey Medical Foundation - Mission Hills
- Desert Oasis Hlthcr Med Group - Palm Springs
- Desert Oasis Hlthcr Med Group - Palm Springs
- Velocity Clin Res- San Bern - San Bernardino
- Linda Vista Health Care Ctr - San Diego
- Velocity Clin Res Santa Ana - Santa Ana
- Premier Medical Center, Inc. - Toluca Lake
Alabama
- Synexus Clin Res-Birmingham - Birmingham
- Univ of Alabama_Birmingham - Birmingham
- Cahaba Research - Pelham
Arizona
- Velocity Clinical Research-Phoenix - Phoenix
- Synexus Rsch /Cnt Phnx Med C - Phoenix
Arkansas
- Arkansas Clinical Research - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,734 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2026-01-06 |
| Phase | Phase 3 |
What the finished NCT06065540 record still lists
NCT06065540 is an interventional study that assigns participants to a tested intervention. Its 2,734 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 2,939-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.
NCT06065540 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06065540 about?
NCT06065540 is a clinical study titled "A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor". The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone....
What is the current status of trial NCT06065540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,734 participants. The study started on 2023-09-27. Estimated completion is 2026-01-06.
What conditions does trial NCT06065540 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT06065540?
The interventions under investigation include: Semaglutide (DRUG), Cagrilintide (DRUG), Placebo cagrilintide (DRUG), Placebo semaglutide (DRUG).
Who is sponsoring clinical trial NCT06065540?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06065540 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06065540's enrollment target sits among peer trials
2,734 7th of 130 higher than 124 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
-
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06085833 · 2,706 participants · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI